Recent research has focused on the potential therapeutic use of CD70 in cancer treatment. One strategy being investigated is the use of antibodies that target CD70. ARGX-110 is a CD70-specific antibody that is currently under investigation for the treatment of hematological malignancies.
Research has recently centered on using CD70 for therapeutic purposes in cancer treatment. A strategy being examined involves antibodies targeting CD70. ARGX-110, a CD70-specific antibody, is presently under investigation as a potential treatment for hematological malignancies.